Introduction: Merkel cell carcinoma (MCC) is a rare, tumor of the skin associated with high recurrence rates and poor survival. Clinical trials have shown activity of checkpoint inhibitors targeting programmed death-(ligand)-1 (PD-(L)1). Avelumab is the only PD-L1 inhibitor that has been approved in the Netherlands for advanced/metastatic MCC (mMCC).
Aim(s): To report the Dutch real-world efficacy data of avelumab in patients (pts) with mMCC.
Materials and methods: All mMCC pts from 4 tertiary referral centers in the Netherlands from December 2016 were analysed. Pts were included in this analysis if they had received avelumab for mMCC, regardless of other previous lines of therapy. Data were collected retrospectively and followed up prospectively after initiation of data collection. Primary endpoints were response rate (RR) and duration of response (DOR), secondary endpoints were progression free survival (PFS), overall survival (OS) and toxicity. Toxicity was evaluated according to CTCAE version 5.0.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Sonja Levy
To read results and conclusion, please login ...
Further abstracts you may be interested in